KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Intangibles (2021 - 2025)

Regeneron Pharmaceuticals (REGN) has 4 years of Intangibles data on record, last reported at $1.4 billion in Q3 2025.

  • For Q3 2025, Intangibles rose 23.28% year-over-year to $1.4 billion; the TTM value through Sep 2025 reached $1.4 billion, up 23.28%, while the annual FY2024 figure was $1.1 billion, 10.59% up from the prior year.
  • Intangibles reached $1.4 billion in Q3 2025 per REGN's latest filing, up from $155.0 million in the prior quarter.
  • Across five years, Intangibles topped out at $1.4 billion in Q3 2025 and bottomed at $155.0 million in Q2 2025.
  • Average Intangibles over 4 years is $995.5 million, with a median of $1.0 billion recorded in 2023.
  • The widest YoY moves for Intangibles: up 23.28% in 2025, down 85.94% in 2025.
  • A 4-year view of Intangibles shows it stood at $915.5 million in 2022, then increased by 13.45% to $1.0 billion in 2023, then increased by 10.59% to $1.1 billion in 2024, then increased by 20.22% to $1.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $1.4 billion in Q3 2025, $155.0 million in Q2 2025, and $1.2 billion in Q1 2025.